Altimmune ALT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $26K+420% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $16.19M+2.3% | $18.41M-6.9% | $14.96M-24.5% | $17.24M-18.5% | $15.83M-26.3% | ||
| $8.05M+34.4% | $10.51M+106% | $5.9M+18.8% | $5.69M+1.7% | $5.99M+12.8% | ||
| $24.24M+11.1% | $28.92M+16.3% | $20.86M-15.8% | $22.93M-14.3% | $21.82M-18.6% | ||
| -$24.24M-11.1% | -$28.89M-16.2% | -$20.86M+15.8% | -$22.92M+14.3% | -$21.82M+18.6% | ||
| $1.07M+106,700% | $876K+87,500% | $495K+8,150% | $264K+26,300% | $1K0.0% | ||
| $1.68M+7.8% | $1.54M-9.0% | $1.85M-4.0% | $776K-63.1% | $1.56M-35.0% | ||
| -$22.56M-11.4% | -$27.36M-18.0% | -$19.01M+16.8% | -$22.15M+10.1% | -$20.26M+17.0% | ||
| —— | —— | —— | —— | -$681K— | ||
| -$22.56M-15.3% | -$27.36M-18.0% | -$19.01M+16.8% | -$22.15M+10.1% | -$19.58M+19.8% | ||
| -$0.18+30.8% | -$0.26+21.2% | -$0.21+34.4% | -$0.27+22.9% | -$0.26+23.5% | ||
| -$24.22M-11.2% | -$28.87M-16.2% | -$20.83M+15.8% | -$22.89M+14.2% | -$21.79M+18.4% | ||
| -$24.24M-11.1% | -$28.89M-16.2% | -$20.86M+15.8% | -$22.92M+14.3% | -$21.82M+18.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Altimmune profitable?
- Altimmune is not currently profitable: it reported a net loss of $91.1M over the trailing twelve months, a -214861.0% net margin.
- What is Altimmune's earnings per share?
- Altimmune's diluted EPS over the trailing twelve months is $-0.92.
- Where does Altimmune's income statement data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.